A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model....
A new study, released on the bioRxiv* preprint server, shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host...
The lack of new or repurposed drugs to treat patients with severe or critical coronavirus disease 2019 (COVID-19) has been one of the biggest hurdles to reducing mortality rates in the ongoing pandemic...
Researchers in the United States, UK, and Canada have published a commentary challenging the suggestion that the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may not be...
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression...
The rollout of vaccines is on in an attempt to achieve population immunity against the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)....
A new study published in the journal Science Immunology analyzed lung epithelial cells from patients infected with COVID-19 and found the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...
A team of scientists from the University of California Santa Cruz, USA, recently identified a novel variant (B.1.x) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that might be circulating...
The effect of different neutralizing antibodies, both vaccine-elicited and from convalescent sera, suggests new variants are emerging that can evade the human immune response.
The severe acute respiratory...
Evolutionary ecology theory offers avenues to anticipate the future behavior of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen. The repeated emergence of more infectious and...
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok